<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p241" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_241{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_241{left:306px;bottom:30px;}
#t3_241{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_241{left:346px;bottom:30px;}
#t5_241{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_241{left:517px;bottom:30px;}
#t7_241{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_241{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_241{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_241{left:1105px;bottom:27px;letter-spacing:0.25px;}
#tb_241{left:35px;bottom:777px;letter-spacing:0.04px;word-spacing:0.14px;}
#tc_241{left:35px;bottom:759px;letter-spacing:0.05px;word-spacing:0.14px;}
#td_241{left:35px;bottom:739px;letter-spacing:0.08px;word-spacing:0.11px;}
#te_241{left:35px;bottom:720px;letter-spacing:0.03px;word-spacing:0.16px;}
#tf_241{left:35px;bottom:700px;letter-spacing:0.16px;}
#tg_241{left:396px;bottom:700px;}
#th_241{left:35px;bottom:665px;letter-spacing:0.07px;word-spacing:0.12px;}
#ti_241{left:35px;bottom:645px;letter-spacing:0.1px;word-spacing:0.09px;}
#tj_241{left:35px;bottom:625px;letter-spacing:0.1px;word-spacing:0.09px;}
#tk_241{left:35px;bottom:606px;letter-spacing:0.16px;}
#tl_241{left:396px;bottom:606px;}
#tm_241{left:35px;bottom:570px;letter-spacing:0.11px;word-spacing:0.08px;}
#tn_241{left:35px;bottom:551px;word-spacing:0.18px;}
#to_241{left:35px;bottom:531px;letter-spacing:0.04px;word-spacing:-0.72px;}
#tp_241{left:35px;bottom:512px;letter-spacing:0.08px;word-spacing:0.1px;}
#tq_241{left:35px;bottom:492px;letter-spacing:0.16px;}
#tr_241{left:386px;bottom:492px;}
#ts_241{left:35px;bottom:457px;letter-spacing:0.08px;word-spacing:-0.51px;}
#tt_241{left:35px;bottom:437px;letter-spacing:0.04px;word-spacing:0.15px;}
#tu_241{left:35px;bottom:418px;letter-spacing:0.04px;word-spacing:0.15px;}
#tv_241{left:35px;bottom:398px;letter-spacing:0.16px;}
#tw_241{left:405px;bottom:398px;}
#tx_241{left:35px;bottom:363px;letter-spacing:0.11px;word-spacing:0.08px;}
#ty_241{left:35px;bottom:343px;letter-spacing:0.08px;word-spacing:0.1px;}
#tz_241{left:35px;bottom:324px;letter-spacing:-0.03px;word-spacing:0.21px;}
#t10_241{left:35px;bottom:304px;letter-spacing:0.09px;word-spacing:0.09px;}
#t11_241{left:35px;bottom:284px;letter-spacing:0.16px;}
#t12_241{left:405px;bottom:284px;}
#t13_241{left:35px;bottom:249px;word-spacing:0.19px;}
#t14_241{left:35px;bottom:229px;letter-spacing:0.06px;word-spacing:0.13px;}
#t15_241{left:35px;bottom:210px;letter-spacing:0.04px;word-spacing:0.15px;}
#t16_241{left:35px;bottom:190px;letter-spacing:0.1px;word-spacing:0.08px;}
#t17_241{left:35px;bottom:172px;letter-spacing:0.1px;word-spacing:0.09px;}
#t18_241{left:35px;bottom:152px;letter-spacing:0.16px;}
#t19_241{left:405px;bottom:152px;}
#t1a_241{left:35px;bottom:116px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1b_241{left:35px;bottom:96px;letter-spacing:0.18px;word-spacing:0.01px;}
#t1c_241{left:35px;bottom:78px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1d_241{left:35px;bottom:58px;letter-spacing:0.03px;word-spacing:-1.07px;}
#t1e_241{left:618px;bottom:777px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1f_241{left:618px;bottom:757px;letter-spacing:-0.38px;}
#t1g_241{left:642px;bottom:757px;letter-spacing:0.12px;}
#t1h_241{left:1168px;bottom:757px;}
#t1i_241{left:618px;bottom:722px;letter-spacing:0.01px;word-spacing:0.18px;}
#t1j_241{left:618px;bottom:702px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1k_241{left:618px;bottom:683px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1l_241{left:618px;bottom:665px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1m_241{left:618px;bottom:645px;letter-spacing:0.16px;}
#t1n_241{left:988px;bottom:645px;}
#t1o_241{left:618px;bottom:608px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1p_241{left:618px;bottom:589px;letter-spacing:0.05px;}
#t1q_241{left:618px;bottom:570px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1r_241{left:618px;bottom:551px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1s_241{left:618px;bottom:531px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1t_241{left:618px;bottom:512px;letter-spacing:0.16px;}
#t1u_241{left:988px;bottom:512px;}
#t1v_241{left:618px;bottom:476px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1w_241{left:618px;bottom:457px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1x_241{left:618px;bottom:437px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1y_241{left:618px;bottom:418px;letter-spacing:0.01px;word-spacing:0.18px;}
#t1z_241{left:618px;bottom:398px;letter-spacing:0.08px;word-spacing:0.11px;}
#t20_241{left:618px;bottom:363px;letter-spacing:0.09px;word-spacing:0.1px;}
#t21_241{left:618px;bottom:343px;letter-spacing:0.06px;word-spacing:0.13px;}
#t22_241{left:618px;bottom:324px;letter-spacing:0.04px;word-spacing:0.14px;}
#t23_241{left:618px;bottom:304px;letter-spacing:0.16px;}
#t24_241{left:988px;bottom:304px;}
#t25_241{left:618px;bottom:269px;letter-spacing:0.02px;word-spacing:0.17px;}
#t26_241{left:618px;bottom:249px;letter-spacing:-0.01px;word-spacing:0.2px;}
#t27_241{left:618px;bottom:229px;letter-spacing:0.14px;word-spacing:0.05px;}
#t28_241{left:618px;bottom:210px;letter-spacing:0.1px;word-spacing:0.09px;}
#t29_241{left:618px;bottom:190px;letter-spacing:0.16px;}
#t2a_241{left:988px;bottom:190px;}
#t2b_241{left:618px;bottom:155px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2c_241{left:618px;bottom:135px;letter-spacing:0.04px;word-spacing:0.15px;}
#t2d_241{left:618px;bottom:116px;letter-spacing:0.04px;word-spacing:0.14px;}
#t2e_241{left:618px;bottom:96px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2f_241{left:618px;bottom:77px;letter-spacing:0.16px;}
#t2g_241{left:979px;bottom:77px;}
#t2h_241{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_241{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_241{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_241{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_241{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_241{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_241{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s6_241{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts241" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg241Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg241" style="-webkit-user-select: none;"><object width="1210" height="935" data="241/241.svg" type="image/svg+xml" id="pdf241" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_241" class="t s0_241">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_241" class="t s1_241">© </span>
<span id="t3_241" class="t s0_241">(NCCN </span>
<span id="t4_241" class="t s1_241">© </span>
<span id="t5_241" class="t s0_241">), All rights reserved. NCCN Guidelines </span>
<span id="t6_241" class="t s1_241">® </span>
<span id="t7_241" class="t s0_241">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_241" class="t s2_241">NCCN Guidelines Version 4.2024 </span>
<span id="t9_241" class="t s2_241">Head and Neck Cancers </span>
<span id="ta_241" class="t s3_241">MS-100 </span>
<span id="tb_241" class="t s4_241">550. Zhang L, Zhang Y, Huang P-Y, et al. Phase II clinical study of </span>
<span id="tc_241" class="t s4_241">gemcitabine in the treatment of patients with advanced nasopharyngeal </span>
<span id="td_241" class="t s4_241">carcinoma after the failure of platinum-based chemotherapy. Cancer </span>
<span id="te_241" class="t s4_241">Chemother Pharmacol 2008;61:33-38. Available at: </span>
<span id="tf_241" class="t s5_241">http://www.ncbi.nlm.nih.gov/pubmed/17909810</span><span id="tg_241" class="t s4_241">. </span>
<span id="th_241" class="t s4_241">551. Colevas AD. Chemotherapy options for patients with metastatic or </span>
<span id="ti_241" class="t s4_241">recurrent squamous cell carcinoma of the head and neck. J Clin Oncol </span>
<span id="tj_241" class="t s4_241">2006;24:2644-2652. Available at: </span>
<span id="tk_241" class="t s5_241">http://www.ncbi.nlm.nih.gov/pubmed/16763278</span><span id="tl_241" class="t s4_241">. </span>
<span id="tm_241" class="t s4_241">552. Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II </span>
<span id="tn_241" class="t s4_241">evaluation of paclitaxel in patients with advanced squamous cell </span>
<span id="to_241" class="t s4_241">carcinoma of the head and neck: an Eastern Cooperative Oncology Group </span>
<span id="tp_241" class="t s4_241">trial (PA390). Cancer 1998;82:2270-2274. Available at: </span>
<span id="tq_241" class="t s5_241">http://www.ncbi.nlm.nih.gov/pubmed/9610709</span><span id="tr_241" class="t s4_241">. </span>
<span id="ts_241" class="t s4_241">553. Mai HQ, Chen QY, Chen D, et al. Toripalimab plus chemotherapy for </span>
<span id="tt_241" class="t s4_241">recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 </span>
<span id="tu_241" class="t s4_241">randomized clinical trial. JAMA 2023;330:1961-1970. Available at: </span>
<span id="tv_241" class="t s5_241">https://www.ncbi.nlm.nih.gov/pubmed/38015220</span><span id="tw_241" class="t s4_241">. </span>
<span id="tx_241" class="t s4_241">554. Wang FH, Wei XL, Feng J, et al. Efficacy, safety, and correlative </span>
<span id="ty_241" class="t s4_241">biomarkers of toripalimab in previously treated recurrent or metastatic </span>
<span id="tz_241" class="t s4_241">nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin </span>
<span id="t10_241" class="t s4_241">Oncol 2021;39:704-712. Available at: </span>
<span id="t11_241" class="t s5_241">https://www.ncbi.nlm.nih.gov/pubmed/33492986</span><span id="t12_241" class="t s4_241">. </span>
<span id="t13_241" class="t s4_241">555. Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in </span>
<span id="t14_241" class="t s4_241">combination with gemcitabine and cisplatin as first-line treatment for </span>
<span id="t15_241" class="t s4_241">recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a </span>
<span id="t16_241" class="t s4_241">multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol </span>
<span id="t17_241" class="t s4_241">2021;22:1162-1174. Available at: </span>
<span id="t18_241" class="t s5_241">https://www.ncbi.nlm.nih.gov/pubmed/34174189</span><span id="t19_241" class="t s4_241">. </span>
<span id="t1a_241" class="t s4_241">556. Zhang L, Yang Y, Pan J, et al. RATIONALE-309: updated </span>
<span id="t1b_241" class="t s4_241">progression-free survival (PFS), PFS after next line of treatment, and </span>
<span id="t1c_241" class="t s4_241">overall survival from a phase 3 double-blind trial of tislelizumab versus </span>
<span id="t1d_241" class="t s4_241">placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic </span>
<span id="t1e_241" class="t s4_241">nasopharyngeal cancer. J Clin Oncol 2022;40:384950-384950. Available </span>
<span id="t1f_241" class="t s4_241">at: </span><span id="t1g_241" class="t s5_241">https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.36_suppl.384950</span><span id="t1h_241" class="t s4_241">. </span>
<span id="t1i_241" class="t s4_241">557. Hsu C, Lee SH, Ejadi S, et al. Safety and antitumor activity of </span>
<span id="t1j_241" class="t s4_241">pembrolizumab in patients with programmed death-ligand 1-positive </span>
<span id="t1k_241" class="t s4_241">nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin </span>
<span id="t1l_241" class="t s4_241">Oncol 2017;35:4050-4056. Available at: </span>
<span id="t1m_241" class="t s5_241">https://www.ncbi.nlm.nih.gov/pubmed/28837405</span><span id="t1n_241" class="t s4_241">. </span>
<span id="t1o_241" class="t s4_241">558. Marabelle A, Fakih M, Lopez J, et al. Association of tumour </span>
<span id="t1p_241" class="t s4_241">mutational burden with outcomes in patients with advanced solid tumours </span>
<span id="t1q_241" class="t s4_241">treated with pembrolizumab: prospective biomarker analysis of the </span>
<span id="t1r_241" class="t s4_241">multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol </span>
<span id="t1s_241" class="t s4_241">2020;21:1353-1365. Available at: </span>
<span id="t1t_241" class="t s5_241">https://www.ncbi.nlm.nih.gov/pubmed/32919526</span><span id="t1u_241" class="t s4_241">. </span>
<span id="t1v_241" class="t s4_241">559. Delord JP, Hollebecque A, de Boer JP, et al. An open-label, </span>
<span id="t1w_241" class="t s4_241">multicohort, phase I/II study to evaluate nivolumab in patients with virus- </span>
<span id="t1x_241" class="t s4_241">associated tumors (CheckMate 358): Efficacy and safety in recurrent or </span>
<span id="t1y_241" class="t s4_241">metastatic (R/M) nasopharyngeal carcinoma (NPC). [abstract]. Presented </span>
<span id="t1z_241" class="t s4_241">at the ASCO Annual Meeting. 6025. </span>
<span id="t20_241" class="t s4_241">560. Sato H, Fushimi C, Okada T, et al. Investigation of the efficacy and </span>
<span id="t21_241" class="t s4_241">safety of nivolumab in recurrent and metastatic nasopharyngeal </span>
<span id="t22_241" class="t s4_241">carcinoma. In Vivo 2020;34:2967-2972. Available at: </span>
<span id="t23_241" class="t s5_241">https://www.ncbi.nlm.nih.gov/pubmed/32871839</span><span id="t24_241" class="t s4_241">. </span>
<span id="t25_241" class="t s4_241">561. Ma BBY, Lim WT, Goh BC, et al. Antitumor activity of nivolumab in </span>
<span id="t26_241" class="t s4_241">recurrent and metastatic nasopharyngeal carcinoma: an international, </span>
<span id="t27_241" class="t s4_241">multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J </span>
<span id="t28_241" class="t s4_241">Clin Oncol 2018;36:1412-1418. Available at: </span>
<span id="t29_241" class="t s5_241">https://www.ncbi.nlm.nih.gov/pubmed/29584545</span><span id="t2a_241" class="t s4_241">. </span>
<span id="t2b_241" class="t s4_241">562. Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to </span>
<span id="t2c_241" class="t s4_241">standard chemoradiation for locoregionally advanced nasopharyngeal </span>
<span id="t2d_241" class="t s4_241">carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol </span>
<span id="t2e_241" class="t s4_241">2012;13:172-180. Available at: </span>
<span id="t2f_241" class="t s5_241">http://www.ncbi.nlm.nih.gov/pubmed/22178121</span><span id="t2g_241" class="t s4_241">. </span>
<span id="t2h_241" class="t s6_241">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
